To review the pharmacology, safety, efficacy, and the role of rucaparib in the treatment of relapsed, advanced ovarian cancer.
Summary:
A total of 2 phase I/II trials and 1 phase II trial have evaluated the safety and efficacy of oral rucaparib in ovarian cancer. In patients with deleterious BRCA1/2 mutation, an overall response rate of 80% was achieved in the phase II trial Assessment of Rucaparib in Ovarian CancEr Trial 2 (ARIEL2). In the same trial, progression-free survival was higher in patients with BRCA1/2 mutation and BRCA wild types with high loss of heterozygosity (LOH) than BRCA wild types with low LOH. Rucaparib was found to be relatively well tolerated in clinical trials, with the most common adverse events being anemia, fatigue, and nausea.
Conclusion:
Rucaparib appears to be a safe and effective new option in the treatment of relapsed, advanced BRCA1/2 mutant ovarian cancer. The role of rucaparib in this setting will likely expand and be further elucidated as results from several ongoing studies become available.
SiegelRLMillerKDJemalA. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.21387. Epub 2017 Jan 5.
2.
KurmanRJShihleM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm. Hum Pathol. 2011;42(7):918–931. doi:10.1016/j.humpath.2011.03.003.
3.
AbkevichVTimmsKMHennesyBT. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer2012;107(10):1776–1782. doi:10.1038/bjc.2012.451.
4.
YoshidaKMikiY. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 2004;95(11):866–871.
5.
Levy-LahadEFriedmanE. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2007;96(1):11–15.
6.
JelovacDArmstrongDK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61(3):183–203. doi:10.3322/caac.20113.
7.
Du BoisALückHJMeierW; Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95(17):1320–1329.
8.
LeeJMLedermannJAKohnEC. PARP inhibitors for BRCA 1/2 mutation-associated and BRCA-like malignancies. Ann Oncol. 2014;25(1):32–40. doi:10.1093/annonc/mdt384.
Lynparza (olaparib) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2017.
11.
DomchekSMAghajanianCShapira-FrommerR. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol. 2016;40(2):199–203. doi:10.1016/j.ygyno.2015.12.020.
Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–615. doi:10.1038/nature10166.
15.
ThomasHDCalabreseCRBateyMA. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther2007;6(3):945–956.
16.
MuraiJHuangSYDasBB. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72(21):5588–5599. doi: 10.1158/0008-5472.CAN-12-2753.
17.
GirolimettiGPerroneASantiniD. BRCA-associated ovarian cancer: from molecular genetics to risk management. Biomed Res Int. 2014;2014:787143. doi:10.1155/2014/787143.
18.
HelledayT. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011;5(4):387–393.
19.
BryantHESchultzNThomasHD. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–917.
20.
KristeleitRShapiroGIBurrisHA. A phase I-II study of oral poly(ADP-ribose) polymerase inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors. Clin Cancer Res. 2017;23(15):4094–4106. doi:10.1158/1078-0432.CCR-16-2796.
21.
SwisherEMLinKKOzaAM. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicenter, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75–87. doi:10.1016/S1470-2045(16)30559-9.
22.
EisenhauerEATherassePBogaertsJ. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
23.
RustinGJVergoteIEisenhauerE. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21(2):419–423.
24.
DrewYLedermannJHallG. Phase 2 multicentre trial investigating intermittent and continuous dosing schedule of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carrier with advanced ovarian and breast cancer. Br J Cancer. 2016;114(7):723–730. doi:10.1038/bjc.2016.41.
25.
Olaparib: drug information. In: UpToDate [online database]. Waltham, MA: UpToDate, Inc.
26.
Rucaparib: drug information. In: UpToDate [online database]. Waltham, MA: UpToDate, Inc.
